Objective: To compare potentials of magnetic resonance imaging (MRI), F-18 FDG, and 11C-Choline PET/CT in differentiating brain tumor recurrence from necrosis after radiotherapy. Methods: Fifty-five patients with suspected brain tumor recurrence or necrosis after radiotherapy underwent MRI, F-18 FDG, and 11C-choline PET/CT examinations, and all the patients were followed up for at least 11 months. Lesion diagnoses based on medical imaging were compared with pathology or follow-up outcomes. Results: The sensitivities of MRI, F-18 FDG PET/CT, and 11C-Choline PET/CT in lesion diagnosis were 87.2%, 76.9%, and 92.3%, respectively, and their specificities were 81.3%, 62.5%, and 87.5%, respectively.
R adiotherapy plays an important role in brain tumor therapeutics.
Cerebral necrosis is an iatrogenic complication after radiotherapy. Accurate differentiation of radiation injury from tumor recurrence may influence the selection of therapeutic regimen and prognosis. However, differentiating tumor recurrence from cerebral necrosis after radiotherapy may be difficult with structural imaging techniques because both sources of lesion may have a similar appearance in structural imaging. [1] [2] [3] Early detection of tumor recurrence requires additional functional and/or biochemical imaging modalities to complement structural information. 4, 5 Fluorine-18 fluorodeoxyglucose (F-18 FDG) is widely used in the diagnosis of brain tumors. 6, 7 However, FDG PET imaging has found a lower sensitivity and/or specificity in the assessment of some types of cancer, which stimulated efforts to develop new oncological tracers for PET imaging. 8, 9 Hara et al 10 developed a simple method to synthesize methyl-11C-choline (11C-choline), which can be used for tumor identification in PET studies. Phosphatidylcholine is a major phospholipid component of membranes in mammalian cells and it is synthesized from choline via CDP-choline pathway (Kennedy pathway) of phospholipid biosynthesis. 11 Phospholipids, such as phosphatidylcholine, have been determined to influence cell proliferation and differentiation. 12 Malignant tumors contain high amounts of phospholipid, particularly phosphatidylcholine. 13 Malignant cells have high levels of choline kinase activity, resulting in increased level of phosphorylcholine, an intermediate product involved in phospholipids synthesis. 14 For this reason, 11C-choline is widely used in PET studies for diagnosis of tumors. Comparison of 11C-Choline with FDG PET or magnetic resonance imaging (MRI) for the differential diagnosis of malignant tumors had been performed in several studies. [15] [16] [17] However, little information is available on the clinical utility of 11C-choline PET in differentiating brain tumor recurrence from necrosis after radiotherapy compared with FDG PET and MRI. The purpose of this study was to conduct such a comparison and provide some suggestions to physicians when they select following therapeutic regimens.
MATERIALS AND METHODS

Patient Population
The study comprised 55 subjects (male, 45; female, 10; age range, 17-79 years; mean age, 56.6 Ϯ 16.7 years) with brain tumor suspected to have tumor recurrence or radiation injury after radiotherapy between October 2007 and September 2009. Thirty-seven patients had glioma; 1, brain neuroblastoma; 1, brain lymphoma; 1, brain germinoma; and 15, brain metastasis (9 lung cancer, 2 breast carcinoma, 1 bladder carcinoma, 1 renal carcinoma, 1 nasopharyngeal carcinoma, 1 unknown primary tumor). All the subjects had their symptoms within 11 months after radiotherapy. All subjects underwent physical examination and were examined with MRI, F-18 FDG, and 11C-Choline PET/CT. No complication, which might induce injury of central nervous system, was found except radiotherapy. None of them had any invasive examination.
PET/CT Acquisition
PET/CT scans were performed with a Biograph Sensation 64 PET/CT scanner (Siemens Medical Solutions, Germany). Each patient was studied with 11C-choline PET/CT and FDG PET/CT after overnight fasting. 11C-choline PET/CT scans were performed at 5 minutes after the intravenous injection of 370 MBq 11C-choline. FDG PET/CT scans were commenced at 60 minutes after the administration of 275-370 MBq FDG. Attenuation correction of PET images with CT, image reconstruction, and fusion were processed automatically. Images were reconstructed using iterative ordered-subset expectation maximization weighted attenuation algorithm. The number of reconstruction times was 6, and number of subsets was 16. PET and CT images were fused. MSV software installed on a Wizard workstation was used to view the images. Regions of interest were drawn manually. 
MRI Acquisition
Assessments
All PET images were analyzed separately by 2 nuclear medicine physicians to reach a consensus. An increased tracer uptake relative to the surrounding background radioactivity was considered as a positive result for a tumor. CT and MR images were visually reviewed by 2 radiology physicians in all standard planes.
Pathologic Diagnosis and Follow-Up
Seventeen subjects were confirmed by pathology (glioma grade IV, 7 cases; glioma grade III, 3 cases; glioma grade II, 1 case; brain metastasis recurrent, 1 case; radiation injury, 5 cases). Four subjects were confirmed to have recurrent tumors by the results of stereotaxis puncture biopsy. Other subjects were followed up with MRI examination every 3 months. It was considered to be a radiation injury if a lesion was found to become smaller or to be responsive to the treatment; otherwise, it was considered to be a recurrence. Each subject was followed up for at least 11 months, and the rate of follow-up was up to 100%. Results from pathology and follow-up were compared with imaging results, and the corresponding sensitivities and specificities were calculated.
Statistical Analysis
Sensitivities and specificities for the 3 imaging methods were determined based on the agreed image interpretation, and confirmed either by pathologic verification or clinical follow-up.
RESULTS
It was confirmed by pathology and follow-up that 39 subjects had recurrences, and the other 16 subjects had radiation injuries. The results of the 55 subjects were summarized in Table 1 . 11C-Choline PET/CT found that 38 subjects had increased uptake in their lesions, which were diagnosed as recurrences. Two of these were falsepositive, one was gliosis and the other was granuloma. It was found that the other 17 subjects had a decreased uptake or uptake deficiency in their lesions and were diagnosed as radiation injuries, among which 3 were false negative. On the basis of F-18 FDG PET/CT, 36 subjects were diagnosed as recurrence, the other 19 as radiation injuries. MRI found that 37 subjects had recurrences and 18 had radiation injuries.
These results showed that the sensitivities for MRI, F-18 FDG PET/CT, and 11C-Choline PET/CT in lesion diagnosis were 87.2%, 76.9%, and 92.3%, respectively. The specificities were 81.3%, 62.5%, and 87.5%, respectively.
DISCUSSION
During the past several decades, therapies for patients with primary or metastatic CNS tumors had become more aggressive, as neurosurgeons, neuro-oncologists, and radiation oncologists tried to cure patients or at least provide them with a longer disease-free survival. Surgical resection or chemotherapy alone has been proved to be insufficient in many instances. As a result, various forms of radiotherapy, including high-dose external beam radiation, radiosurgery, and radioactive seed implantation, have become important therapeutic adjuncts. However, these radiotherapies are causing an increased incidence of radionecrosis.
Unfortunately, distinguishing radionecrosis from tumor recurrence or viable residual tumor has proved to be a particularly difficult task. Differentiation on the basis of clinical signs and symptomatology has not been possible. However, it is important for clinicians to confirm a radiation injury or a recurrence before they choose therapeutic regimens.
Imaging technique is playing a more and more important role in distinguishing radionecrosis from tumor recurrent. MRI and PET are widely used in the diagnosis of brain tumors 6,7,18 -22 and in determining the effects of radiation therapy. However, some studies suggested that the capability of MRI and FDG PET to differentiate recurrent tumor from radiation necrosis is limited, and there are still high rates of false-positive and false negative. 16, 23 In this study, the results showed that there were some overlaps, false-positive and false negative in distinguishing radiation necrosis from recurrence with MRI and F-18 PET/CT (Figs. 1, 2) , F-18 PET/CT had the lowest sensitivity and specificity among the 3 methods.
Therefore, the efforts have been made to seek alternative non-FDG tracer to improve diagnostic accuracy. It is well known Clinical Nuclear Medicine • Volume 36, Number 11, November 2011 Differentiating Brain Tumor Recurrence From Necrosis that choline is one of the components of cell membrane. Choline is scarcely accumulated in normal brain tissues while its uptake is much higher in brain tumors. 24 This may be used to improve the diagnostic accuracy of 11C-Choline PET/CT in distinguishing tumor recurrence from necrosis. This study showed that 11C-Choline PET/CT had a sensitivity of 92.3% and a specificity of 87.5%, both of which were significantly higher than those for MR and FDG PET/CT imaging. 11C-Choline PET/CT imaging also had falsepositive and false negative. There were 2 cases of false-positive in this study: one was gliosis and the other was granuloma ( Fig. 3) , which might be related to active proliferative cells surrounding the lesion after radiotherapy. There were 3 cases of false negative; one of which was grade II astrocytoma and might be related to good differential status. The other 2 cases were grade IV glioblastomas, and their false-negative appearance might be because of a relatively short period (Ͻ3 months) following the completion of radiation therapy. Radiotherapy might directly inhibit the tumor uptake. It was reported that the false negative of 11C-Choline PET/CT imaging was mainly related to tumor rating and blood supply. The uptake of 11C-Choline was always lower in low-grade gliomas and always higher in high-grade gliomas. 25 In addition, blood supply also influences the uptake of 11C-Choline. Some brain tumors with high blood supply, such as meningiomas and hemangioblastoma, have a higher uptake, whereas those with low blood supply, such as astrocytoma, have a lower uptake. 24 
CONCLUSIONS
In conclusion, 11C-Choline PET/CT imaging provides an effective means to distinguish brain tumor recurrence from radiation injury. For cases which are difficult to be distinguished by MRI and F-18 FDG PET/CT, 11C-Choline PET/CT imaging may be a good option. However, as 11C-Choline PET/CT imaging also had false negative, it is still necessary to combine it with clinical assessment when selecting therapeutic regimen.
FIGURE 2.
A 68-year-old man presented 4 months after radiotherapy for intracranial metastasis. A, T1-weighted gadolinium-enhanced MRI showed a ring-like enhanced lesion in the in left cerebellum (arrow). B, FDG PET demonstrated a decreased FDG uptake (arrow). C, 11C-choline PET demonstrated a marked 11C-choline uptake (arrow). Four months later, the patient underwent MRI again, which showed that the lesion in left cerebellum expanded, indicating a recurrence.
FIGURE 3.
A 58-year-old man presented 2 years after radiotherapy for glioma (grade II). T1-weighted gadolinium-enhanced MRI showed an enhanced lesion in the right frontal lobe. A, FDG PET demonstrated a marked uptake of FDG (arrow). B, 11C-choline PET demonstrated a marked uptake of 11C-choline (arrow). The pathologic diagnosis was granuloma, which was considered to be related to radiotherapy.
